Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03NLQ
|
|||
| Former ID |
DNCL001954
|
|||
| Drug Name |
ABT-957
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 1 | [1] | |
| Company |
Abbott Laboratories
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Calpain-2 (CAPN2) | Target Info | Modulator | [2] |
| KEGG Pathway | Protein processing in endoplasmic reticulum | |||
| Apoptosis | ||||
| Alzheimer's disease | ||||
| Reactome | Degradation of the extracellular matrix | |||
| WikiPathways | Focal Adhesion | |||
| Integrated Pancreatic Cancer Pathway | ||||
| Alzheimers Disease | ||||
| Integrin-mediated Cell Adhesion | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02220738) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors. U.S. National Institutes of Health. | |||
| REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.